IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

FEB 1 3_2000

In rethe application of: Timothy A. Springer et al.

TRADES Erial No.: 09/945,265

Filed: August 31, 2001

"Modified Polypeptides Stabilized in a For:

Desired Conformation and Methods

for Producing Same"

Attorney Docket No.: CBN-002CP

Group Art Unit: 1645

Examiner: Not Yet Assigned

Commissioner for Patents Box Missing Parts Washington, D.C. 20231

Attn: Official Draftsperson

TRANSMITTAL OF FORMAL DRAWINGS

Dear Sir:

In response to the Notice to File Missing Parts of Nonprovisional Application dated October 18, 2001, transmitted herewith are Thirteen (13) Sheets of Formal Drawings (Figures 1, 2A-D, 3A-B, 4A-B, 5, 6, 7, 8A-C, 9A-F, 10A-B, 11A-C and 12A-C). Applicants respectfully submit that the formal drawings are in compliance with 37 C.F.R. 1.84. Applicants request that the drawings presently on file be replaced with the enclosed Formal Drawings for the abovereferenced application. No new matter has been added.

Please charge any fees in connection with this matter to Deposit Account No. 12-0080. For this purpose, a duplicate of this sheet is enclosed.

Certificate of First Class Mailing (37 CFR 1.8(a)) I hereby certify that this transmittal letter and the papers referred to as being enclosed therein are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Box Missing Parts, Washington, DC 20231 on: 2002 Registration No. 46,931 Debra J. Milasincic

LAHIVE & COCKFIELD, LLP

Attorneys at Law

Debra J-Milasincic, Esq. Registration No. 46,931 Attorney for Applicants

Date: January 18, 2002

FIG. 1







FIG.2C low affinity structure







FIG. 5




Log Fluorescence Intensity

40 Cells bound (% of input) 30 20 10 -7 50 0 0 7 60 30 40 7- 10 20 Lovastatin (μM)

MOCK WT/Mn WT/CBRLFA1/2 HA/aLb2

FIG. 7



Log Fluorescence Intensity

FIG. 8B FIG. 8A 40 □ EDTA
□ Mg²⁺
■ Mn²⁺ 40 ■ L15 □ L15 + DTT 30 % Bound Cells 30 % Bound Cells 20 20 10 10 mock E 0 0 VT (#1)-(287C/K294C (#2)-L289C/K294C (#2) -WT (#2)-289C/K294C (#1) -K287C/K294C (#1)-WT (#1) · mock 289C/K294C (#1) intact LFA-1 isolated I-domain isolated I-domain FIG. 8C 30 K287C/K294C I-domain (#1) intact LFA-1+CBRLFA-1/2 % Bound Cells 20 10 CBRLFA1/1-5 25.3.1-TS2/14-0 TS1/11-TS1/22 -TS2/6 -CBRLFA1/9-





FIG. 9C






FIG. 9F




FIG. 10A




FIG. 10B




FIG. 12A

Wild-type

Q163/Q309C

D294C/Q311C




FIG. 12B





FIG. 12C



L15/Mn L15/Mn/CBRM1/5

L15/Mn/DTT